Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 公司指定的信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资 讯网(http://www.cninfo.com.cn)，公司所有信息均以在上述指定媒体刊登的信息为准。 敬请广大投资者理性投资，注意投资风险。 特此公告。 瑞康医药集团股份有限公司 证券代码：002589 证券简称：瑞康医药 公告编号：2025-040 瑞康医药集团股份有限公司 关于公司董事、董事会秘书及副总裁解除留置并变更为责令候查的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 瑞康医药集团股份有限公司（以下简称"公司"）于2025年7月3日披露了《关于公司董事、董事会秘书及 副总裁被采取留置措施的公告》（公告编号：2025-037），公司董事、董事会秘书及副总裁李喆先生被 实施留置措施。 公司于2025年8月12日收到济南市济阳区监察委员会签发的《变更留置通知书》，济南市济阳区监察委 员会已解除对李喆先生的留置措施，变更为责令候查措施。目前公司生产经营情况正常，李喆先生能够 正常履行董事、董事会秘书及副总裁 ...

Group 1: China Unicom - Company revenue exceeded RMB 200 billion in the first half of the year, with a total profit of RMB 17.7 billion, representing a year-on-year increase of 5.2% [1] - Internet communication revenue reached RMB 131.9 billion, while intelligent network revenue amounted to RMB 45.4 billion, accounting for 26% of total revenue [1] - The number of connected users surpassed 1.2 billion, with mobile and broadband users increasing by over 11 million, reaching a total of 480 million [1] Group 2: Kweichow Moutai - The net profit for the first half of the year increased by 8.89%, with favorable factors outweighing unfavorable ones [2] Group 3: Shuanghui Development - The company reported a total meat product export volume of 1.57 million tons, a year-on-year increase of 3.67%, and total revenue of RMB 28.5 billion, up 3.00% [4] - The total profit decreased by 2.36%, while the net profit attributable to shareholders rose by 1.17% due to improved profitability in tax-exempt businesses [4] Group 4: Pengding Holdings - The company achieved a revenue of RMB 16.375 billion, a year-on-year increase of 24.75%, and a net profit of RMB 1.233 billion, up 57.22% [6] - The increase in revenue was attributed to a rise in customer orders [6] Group 5: Jinlongyu - The company reported a net profit increase of 60.07%, with revenue reaching RMB 115.68 billion, up from RMB 109.48 billion [9] - The growth in revenue was driven by increased sales of kitchen foods, feed raw materials, and oil technology products [9] Group 6: Other Companies - Zhenray Technology reported a turnaround in net profit due to significant growth in main business revenue [12] - Zhongke Sanhuan achieved a net profit increase of 160.82%, despite a revenue decline of 11.17% [16]

Mergers and Acquisitions - Jin Chengzi plans to issue shares and pay cash to acquire 55% stake in Samit from eight parties including Wang Yongyang and Huang Meng, while also raising supporting funds [1] - Quzhou Development intends to purchase 95.46% of Xian Dao Electronic Technology Co., Ltd. through share issuance and will raise supporting funds [2] Performance Disclosure - Zhuyue Group reported a net profit of 585 million yuan for the first half of 2025, representing a year-on-year increase of 57.83%, with total revenue of 10.412 billion yuan, up 14.89% [3] - Zhenlei Technology announced a net profit of 62.32 million yuan for the first half of 2025, marking a significant year-on-year growth of 1006.99%, with revenue of 205 million yuan, up 73.64% [4] Shareholding Changes - Baichuan Co., Ltd. major shareholder Zheng Tiejiang plans to reduce his stake by up to 3%, equivalent to 17.83 million shares, from September 4 to December 3, 2025, due to personal financial needs [5] - Taiping Bird's shareholder Chen Hongchao intends to reduce his stake by no more than 3%, or 14.13 million shares, from August 19 to November 18, 2025, also for personal financial reasons [6] - Kanghua Biology's shareholder Chuanfa Selected No. 3 plans to reduce his stake by up to 3%, or 389,840 shares, within three months from the disclosure date [7] Risk Matters - *ST Huamei announced it failed to rectify fund occupation issues within the mandated period, leading to a suspension of its stock starting August 13, 2025, with potential delisting risks if not resolved within two months [8] - Ruikang Pharmaceutical reported that its director and board secretary Li Zhe had his detention lifted and changed to a warning measure, with normal business operations continuing [9]

北京商报讯（记者 丁宁）8月12日晚间，瑞康医药（002589）发布公告称，公司于8月12日收到济南市 济阳区监察委员会签发的《变更留置通知书》，济南市济阳区监察委员会已解除对公司董事、董事会秘 书及副总裁李喆的留置措施，变更为责令候查措施。目前公司生产经营情况正常，李喆能够正常履行董 事、董事会秘书及副总裁职责。 ...

格隆汇8月12日丨瑞康医药(002589.SZ)公布，公司于2025年8月12日收到济南市济阳区监察委员会签发 的《变更留置通知书》，济南市济阳区监察委员会已解除对李喆先生的留置措施，变更为责令候查措 施。目前公司生产经营情况正常，李喆先生能够正常履行董事、董事会秘书及副总裁职责。 ...

Mergers and Acquisitions - Jin Chengzi plans to issue shares and pay cash to acquire 55% stake in Samit from eight parties including Wang Yongyang and Huang Meng, while also raising matching funds [1] - Quzhou Development intends to purchase 95.46% of Xian Dao Electronic Technology Co., Ltd. through share issuance and will raise matching funds [2] Earnings Disclosure - Zhuyue Group reported a net profit of 585 million yuan for the first half of 2025, representing a year-on-year increase of 57.83%, with total revenue of 10.412 billion yuan, up 14.89% [3] - Zhenlei Technology announced a net profit of 62.32 million yuan for the first half of 2025, a staggering year-on-year growth of 1006.99%, with revenue of 205 million yuan, increasing by 73.64% [4] Shareholding Changes - Baichuan Co., Ltd. major shareholder Zheng Tiejiang plans to reduce his stake by up to 3%, amounting to no more than 17.83 million shares, due to personal financial needs, from September 4 to December 3, 2025 [5] - Taiping Bird's shareholder Chen Hongchao intends to reduce his stake by no more than 3%, equivalent to 14.13 million shares, for personal financial reasons, from August 19 to November 18, 2025 [6] - Kanghua Biology's shareholder Chuanfa Selected No. 3 plans to reduce his stake by up to 3%, or 389,840 shares, within three months from the 15th trading day after the announcement [7] Risk Matters - *ST Huamei announced that it failed to rectify fund occupation issues within the mandated period, leading to a suspension of its stock starting August 13, 2025, with potential delisting risks if not resolved within two months [8] - Ruikang Pharmaceutical reported that its director and board secretary Li Zhe has had his detention lifted and is now under a directive to be monitored, with normal business operations continuing [9]

证券代码：002589 证券简称：瑞康医药 公告编号：2025-040 瑞康医药集团股份有限公司 关于公司董事、董事会秘书及副总裁解除留置 《上海证券报》、 《证券日报》和巨潮资讯网(http://www.cninfo.com.cn)，公司所有信息均以在上述 指定媒体刊登的信息为准。 敬请广大投资者理性投资，注意投资风险。 特此公告。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日披露 了《关于公司董事、董事会秘书及副总裁被采取留置措施的公告》（公告编号： 公司于 2025 年 8 月 12 日收到济南市济阳区监察委员会签发的《变更留置通 知书》，济南市济阳区监察委员会已解除对李喆先生的留置措施，变更为责令候 查措施。目前公司生产经营情况正常，李喆先生能够正常履行董事、董事会秘书 及副总裁职责。 公司指定的信息披露媒体为《证券时报》、 《中国证券报》、 瑞康医药集团股份有限公司 并变更为责令候查的公告 董 事 会 ...

人民财讯8月12日电，瑞康医药（002589）8月12日晚间公告，公司7月3日披露，公司董事、董事会秘书 及副总裁李喆被实施留置措施。公司于8月12日收到济南市济阳区监察委员会签发的通知书，济南市济 阳区监察委员会已解除对李喆的留置措施，变更为责令候查措施。目前公司生产经营情况正常，李喆能 够正常履行董事、董事会秘书及副总裁职责。 ...

Group 1 - The company, Ruikang Pharmaceutical (002589.SZ), announced that it received a notice from the Jinan Jiuyang District Supervisory Committee on August 12, 2025, regarding the change of detention measures for Li Zhe, which has been lifted and replaced with a directive for supervision [1] - The company's production and operational status is currently normal, and Li Zhe is able to perform his duties normally [1]